Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Yamashita, Hideomi ^a   Kobayashi Shibata, Shino ^a   Terahara, Atsuro ^a   Okuma, Kae ^a   Haga, Akihiro ^a   Wakui, Reiko ^a   Ohtomo, Kuni ^a   Nakagawa, Keiichi ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KREBS VON DEN LUNGEN 6; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; MUC1 PROTEIN, HUMAN; MUCIN 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOGRAM; HUMAN; INCIDENCE; INTERSTITIAL PNEUMONIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; RADIATION PNEUMONIA; RECURRENT CANCER; RISK FACTOR; SCREENING; INTERSTITIAL LUNG DISEASE; LUNG TUMOR; METABOLISM; MIDDLE AGED; RADIOGRAPHY; RADIOSURGERY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUCIN-1; NEOPLASM RECURRENCE, LOCAL; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; RADIATION PNEUMONITIS; RADIOSURGERY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77951959368     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-32     Document Type: Article

References (20)

1. Nagata Y, Negoro Y, Aoki T, et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2002, 52:1041-1046.
2. Matsuo Y, Takayama K, Nagata Y, et al. Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 2007, 68:416-425.
3. Nishio T, Kunieda E, Shirato H, et al. Dosimetric verification in participating institutions in a stereotactic body radiotherapy trial for stage I non-small cell lung cancer: Japan clinical oncology group trial (JCOG0403). Phys Med Biol 2006, 51:5409-5417. 10.1088/0031-9155/51/21/002, 17047260.
4. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001, 51:666-670.
5. Nakagawa K, Aoki Y, Tago M, et al. Megavoltage CT-assisted stereotactic radiosurgery for thoracic tumors original research in the treatment of thoracic neoplasms. Int J Radiat Oncol Biol Phys 2000, 48:449-457.
6. Wulf J, Hädinger U, Oppitz U, et al. Impact of target reproducibility on tumor dose in stereotactic radiotherapy of targets in the lung and liver. Radiother Oncol 2003, 66:141-150. 10.1016/S0167-8140(02)00372-9, 12648785.
7. Hara R, Itami J, Kondo T, et al. Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors. Cancer 2006, 106:1347-1352. 10.1002/cncr.21747, 16475150.
8. Onimaru R, Fujino M, Yamazaki K, et al. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:374-381.
9. Hof H, Muenter M, Oetzel D, et al. Stereotactic single-dose radiotherapy (radiosurgery) of early stage non small-cell lung cancer (NSCLC). Cancer 2007, 110:148-155. 10.1002/cncr.22763, 17516437.
10. Le QT, Loo BW, Ho A, et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol 2006, 1:802-809. 10.1097/01243894-200610000-00008, 17409963.
11. Kong FM, Ten Haken R, Eisbruch A, et al. Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol 2005, 32:S42-54. 10.1053/j.seminoncol.2005.03.009, 16015535.
12. Rubin P, Johnston CJ, Williams JP, et al. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 1995, 33:99-109.
13. Kong FM, Ao X, Wang L, Lawrence TS. The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. Cancer Control 2008, 15:140-150.
14. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839. 10.1200/JCO.2006.07.5937, 17050868.
15. Borst GR, Ishikawa M, Nijkamp J, et al. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol 2009, 91:307-313. 10.1016/j.radonc.2009.02.003, 19321217.
16. Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009, 27:1579-1584. 10.1200/JCO.2008.19.6386, 19255320.
17. Yamashita H, Nakagawa K, Nakamura N, et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2007, 2:21. 10.1186/1748-717X-2-21, 1894806, 17553175.
18. Le QT, Loo BW, Ho A, et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol 2006, 1:802-809. 10.1097/01243894-200610000-00008, 17409963.
19. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002, 165:378-381.
20. Kong FM, Ao X, Wang L, Lawrence TS. The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. Cancer Control 2008, 15:140-150.